Acurx Pharmaceuticals (ACXP) vs Bolt Biotherapeutics (BOLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.0 million vs $6.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | BOLT |
|---|---|---|
| Share price | $1.25 | $3.65 |
| Market cap | $6.95M | $7.03M |
| 1-day change | -3.85% | +1.39% |
| EPS (TTM) | $-2.67 | $-16.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $7.20 |
| 52-week low | $1.23 | $3.10 |
| Distance from 52-week high | -84.34% | -49.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1260.00% | +694.52% |
| Average volume | 125.08K | 26.26K |
| Shares outstanding | 5.56M | 1.93M |
| Employees | 4 | 23 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Healthcare · Biotechnology · 4 employees
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Healthcare · Biotechnology · 23 employees
ACXP vs BOLT FAQ
Which is bigger, Acurx Pharmaceuticals or Bolt Biotherapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.03M compared with $6.95M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and Bolt Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.